[Please keep these entries up to date! See the updating procedure at the end of this post.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: BMY (Apixaban, Belatacept, Ipilimumab).
ABT – Certriad (Crestor+TriLipix): response to FDA’s CRL (issued 3/30/10) expected any day (source: 2Q10 CC).
ABT – Bioresorbable DES: EU launch expected 2013 (pending successful pivotal trial); no guidance yet on US launch.
ACHN – ACH-1625 PI: start phase-2a trial Sep 2010; report 12w data end 2011. ACHN – ACH-2684 PI: file IND 1H11; phase-1b data end 2011. ACHN – ACH-2928 NS5A: file IND 1H11; phase-1b data end 2011. ACHN – Start all-oral ACH-1625 + ACH-2928 program 2012.
ADLR-ADL5849 and 5747 (osteoarthritis) p2a 3q10 ADLR-ADL5747 (post-herpetic neuralgia) p2a early 2011
AGN – LapBand label expansion: FDA advisory panel 12/3/10. AGN – Botox for OAB: sBLA submission 2H10; data presentation at urology conference in 2011 (no PR). AGN – Next-gen neurotoxin for pain: start phase-2 trial 2H10(?). AGN – Latisse for androgenetic alopecia: formulation work in progress; start phase-1 trial 2011.
AMGN – Denosumab: Already approved by FDA and EU for treatment of osteoporosis; PDUFA date for BLA in treatment of bone mets 11/18/10; data from phase-3 trial to prevent bote mets in HRPC (http://clinicaltrials.gov/ct2/show/NCT00286091 ) 4Q10; BLA submission for bone health in non-metastatic cancer 2012-2013.
AMLN – Bydureon (exenatide LAR) second-pass PDUFA date 10/22/10. (Original CRL issued by FDA 3/15/10.)
ANDS – ANA598 phase-2a trial: SVR12 data for patients re-randomized to 12 weeks of SoC: 3Q10 (200mg cohort), 4Q10 (400mg cohort); SVR12/SVR data for patients re-randomized to 24 weeks of SoC: 1H11.
Bayer – Xarelto: see JNJ. Bayer – VEGF Trap-Eye: see REGN.
BMY – Apixaban vs aspirin in AF/stroke prevention: NDA rolling submission based on AVERROES study to be completed in 1Q11. BMY – Apixaban vs warfarin in AF/stroke prevention: data from phase-3 ARISTOTLE study Apr 2011. BMY – Apixaban for VTE prevention appears to be on the back burner (or dead). In Dec 2009, BMY/PFE said a European MAA would occur in 1H10 (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44219816 ), but nary a peep about VTE prevention since then.
BMY – Belatacept: FDA decision on BMY’s response to May 2010 CRL is on hold until BLA fixes manufacturing problems in Puerto Rico.
BMY – Ipilimumab in second-line metastatic melanoma: PDUFA date 12/25/10; European MAA submitted and accepted by EMA for review. BMY – Ipilimumab in first-line metastatic melanoma: data from phase-3 ‘024’ trial testing DTIC±Ipi expected 1Q11. BMY – Ipilimumab in melanoma brain mets: OS data from phase-2 ‘042’ trial 2011 (RR data reported at 2010 ASCO). BMY – Ipilimumab in NSCLC/SCLC: OS data from phase-2 ‘041’ trial 2011 (PFS data for NSCLC reported at 2010 ASCO). Decision has been made to advance to phase-3 in NSCLC.
BMY – Sprycel in first-line CML: PDUFA date 10/28/10.
BPAX – LibiGel: 2,500 enrollment target reached 10/18/10, triggering first unblinding of safety data to ascertain if further enrollment is needed to get enough safety events.
CHTP - Droxidopa in ADHD PII : Due Q1 11 CHTP - Droxidopa in NOH in Parkinsons pts only PIII Study 306 : Due Q2 11. CHTP - CH-4051 Interim PII in RA : Due Q3 11 CHTP - Droxidopa in Fibromyalgia : Due Q4 11
GILD – Standalone Elvitegravir: report phase-3 Elvitegravir-vs-Isentress primary-endpoint (48-week) data early 2011.
GILD – TMC278+Truvada combo pill: submit NDA/MAA 4Q10. GILD will submit the NDA as soon as the FDA accepts JNJ’s TMC278 NDA for review; bioequivalence studies were completed 4/27/10. (See JNJ for further TMC278 info.)
HGSI – Benlysta in SLE: advisory panel 11/16/10, PDUFA date 12/9/10.
INHX – INX-189 HCV polymerase inhibitor: start phase-1b 3-day monotherapy trial early 4Q10; prelim data from phase-1b late 4Q10; final data from phase-1b early 2011.
ITMN – Pirfenidone: FDA issued a CRL requesting a new trial on 5/4/10; EMEA initial response to MAA soon (MAA submitted 3/2/10, initial response had been expected early Jul 2010).
JNJ – TMC278 for HIV: PDUFA date May 2011 (assuming a standard review—NDA submitted 7/26/10). MAA submission 3Q10. (See GILD re TMC278+Truvada combo pill.)
JNJ – Xarelto: reply to FDA’s CRL in VTE prevention (received May 2009) expected in late 2010 (source: 2Q10 CC). Phase-3 data in AF/stroke prevention expected Nov 2010.
JNJ – Remicade/Simponi arbitration with MRK Dec 2010, decision expected early 2011.
JNJ – Nevo drug-eluting stent: EU submission late 2010; FDA submission 2012.
JNJ – PurTox botulinum toxin: submit BLA 4Q10 after completing two phase-3 trials. (First phase-3 trial reported positive data 10/1/08.)
JNJ – Bapineuzumab: ‘301’/‘302’ (N. American) phase-3 trials conducted by JNJ: data in 2H12; int’l phase-3 trials conducted by PFE: data in 2014 (confirmed on PFE’s 1Q10 CC).
JNJ – Telaprevir: see VRTX.
LLY – Bydureon: see AMLN.
MDVN – Dimebon: see PFE.
Merck KGaA – Cladribine NDA in RRMS: PDUFA date 12/5/10. (Rejected in Europe 9/24/10.)
ONTY – Phase-3 trial in Stage III NSCLC: first interim analysis (at 50% of deaths relative to trigger for final analysis): 2H10.
OREX – Contrave NDA: FDA advisory panel 12/7/10, PDUFA date 1/31/11.
PFE – Apixaban: see BMY.
PFE – Bapineuzumab: see JNJ.
PFE – Dimebon: AD program terminated 5/10/10 except the CONCERT study testing Aricept±Dimebon in mild-to-moderate AD. HORIZON study in HD continues.
REGN - Rilonacept in flare prevention upon initiation of allopurinol - results expected in 2010; Rilonacept in flare treatment - results expected in 2010.
REGN - Aflibercept in 3 different ph iii's (total enrollment expected is ~4000). VELOUR (2nd line colorectal + chemo cocktail), VITAL (2nd line NSCLC with docetaxel), VENICE (1st line HRPC with docetaxel + pred)
REGN - VEGF Trap-Eye: results from ph-3 trials in AMD 4Q10.
Roche – Ritonavir-boosted Danoprevir (RG7127) with SoC: phase-2b was supposed to start in 4Q10 (recently delayed from 3Q10); however, a new phase-1 PK study makes it doubtful that the phase-2b trial will actually start in 2010 (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53624063 ).
Roche – RG7128 + SoC: EoT data at AASLD from phase-2b PROPEL study that tests ‘12+12” and ‘8+16’ regimens in geno-1/4. Separate phase-2b testing regimens with 24w of RG7128 + SoC in geno-1/4 started enrollment Feb 2010. (Phase-2b in geno-2/3, originally planned to start 2H10, may be dead—see http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53150504 .)
Roche – INFORM-3 trial of Donoprevir + RG7128 with SVR endpoint: start 1H11; it was delayed from a 2H10 start on ITMN’s 2Q10 CC 7/27/10 (I’m skeptical that it will start at all—Dew).
SPPI - Belinostat (CUP w/ chemo) p2 data by ye10 SPPI - Belinostat (PTCL monotherapy) NDA 2011
TEVA – Copaxone patent litigation: see MNTA. TEVA –“Low-volume” Copaxone: PDUFA date 1/1/11. TEVA – Thrice-weekly formulation of Copaxone: study to start recruiting patients soon (http://clinicaltrials.gov/ct2/show/NCT01067521 ).
TEVA – Laquinimod for MS: potential US launch in mid 2012.
TRBN - TRU015 (RA) 1st p2b re-treatment add'l data 11/10 at ACR 2nd p2b final data 11/10 at ACR
VRTX – Telaprevir+SoC: Complete Telaprevir NDA submission in first- and second-line settings: 4Q10.
VRTX – Telaprevir + VX-222: report phase-2 interim safety, efficacy, and PK data 2H10; SVR data 1H11. (Low-dose all-oral arm was dropped 10/25/10.)
VRTX – VX-509 JAK3 inhibitor: phase-2 interim data 2H10 (trial started Jan 2010).
VRUS – RG7128 and INFORM-n series of trials: see Roche. VRUS – PSI-7977: present final phase-2a data at conference in 2H10, presumably AASLD (top-line results were reported via presented 5/4/10); start 12-week phase-2b trial 4Q10. VRUS – PSI-938: report phase-1 data 3Q10. VRUS – PSI-661 (f/k/a PSI-879): file IND/CTA 4Q10.
VVUS – Qnexa PDUFA date 10/28/10. (Negative vote at advisory panel 7/15/10.)
-- Procedure for Updating Calendar
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old calendar.
2. Make your additions or modifications, inserting new items in alphabetical order.
3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD IDIX MNTA”).
Market Data 
Markets 
AI
